<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shen Y</submitter><funding>National Natural Science Foundation of China</funding><funding>National Natural Science Foundation of China (National Science Foundation of China)</funding><pagination>2924</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6606754</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>Fas induces apoptosis in activated T cell to maintain immune homeostasis, but the effects of non-apoptotic Fas signaling on T cells remain unclear. Here we show that Fas promotes T&lt;sub>H&lt;/sub>9 cell differentiation by activating NF-κB via Ca&lt;sup>2+&lt;/sup>-dependent PKC-β activation. In addition, PKC-β also phosphorylates p38 to inactivate NFAT1 and reduce NFAT1-NF-κB synergy to promote the Fas&lt;sup>-&lt;/sup>induced T&lt;sub>H&lt;/sub>9 transcription program. Fas ligation exacerbates inflammatory bowel disease by increasing T&lt;sub>H&lt;/sub>9 cell differentiation, and promotes antitumor activity in p38 inhibitor-treated T&lt;sub>H&lt;/sub>9 cells. Furthermore, low-dose p38 inhibitor suppresses tumor growth without inducing systemic adverse effects. In patients with tumor, relatively high T&lt;sub>H&lt;/sub>9 cell nu</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Fas signaling-mediated T&lt;sub>H&lt;/sub>9 cell differentiation favors bowel inflammation and antitumor functions.</pubmed_title><pmcid>PMC6606754</pmcid><funding_grant_id>31670877</funding_grant_id><pubmed_authors>Zhang G</pubmed_authors><pubmed_authors>Duan M</pubmed_authors><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Lu C</pubmed_authors><pubmed_authors>Ma Z</pubmed_authors><pubmed_authors>Yang D</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Guo J</pubmed_authors><pubmed_authors>Apetoh L</pubmed_authors><pubmed_authors>Cai Z</pubmed_authors><pubmed_authors>Miao Y</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Shen Y</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors><pubmed_authors>Song Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>Fas signaling-mediated T&lt;sub>H&lt;/sub>9 cell differentiation favors bowel inflammation and antitumor functions.</name><description>Fas induces apoptosis in activated T cell to maintain immune homeostasis, but the effects of non-apoptotic Fas signaling on T cells remain unclear. Here we show that Fas promotes T&lt;sub>H&lt;/sub>9 cell differentiation by activating NF-κB via Ca&lt;sup>2+&lt;/sup>-dependent PKC-β activation. In addition, PKC-β also phosphorylates p38 to inactivate NFAT1 and reduce NFAT1-NF-κB synergy to promote the Fas&lt;sup>-&lt;/sup>induced T&lt;sub>H&lt;/sub>9 transcription program. Fas ligation exacerbates inflammatory bowel disease by increasing T&lt;sub>H&lt;/sub>9 cell differentiation, and promotes antitumor activity in p38 inhibitor-treated T&lt;sub>H&lt;/sub>9 cells. Furthermore, low-dose p38 inhibitor suppresses tumor growth without inducing systemic adverse effects. In patients with tumor, relatively high T&lt;sub>H&lt;/sub>9 cell nu</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Jul</publication><modification>2026-05-06T22:50:19.57Z</modification><creation>2019-07-25T07:03:00Z</creation></dates><accession>S-EPMC6606754</accession><cross_references><pubmed>31266950</pubmed><doi>10.1038/s41467-019-10889-4</doi></cross_references></HashMap>